Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2436
{ "count": 24866, "next": "http://api.gregory-ms.com/articles/?format=api&page=2437", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2435", "results": [ { "article_id": 523, "title": "Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases", "summary": "<div><p>Metab Brain Dis. 2021 Mar 12. doi: 10.1007/s11011-021-00712-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">In Part I of this Review we evaluated the scientific evidence for a Metabolic Model of multiple sclerosis (MS). Part II outlines the implementation of an adaptive pathology-supported genetic testing (PSGT) algorithm aimed at preventing/reversing disability in two illustrative MS cases, starting with a questionnaire-based risk assessment, including family history and lifestyle factors. Measurement of iron, vitamin B12, vitamin D, cholesterol and homocysteine levels identified biochemical deficits in both cases. Case 1, after following the PSGT program for 15 years, had an expanded disability status scale (EDSS) of 2.0 (no neurological sequelae) together with preserved brain volume on magnetic resonance imaging (MRI). A novel form of iron deficiency was identified in Case 1, as biochemical testing at each hospital submission due to MS symptoms showed low serum iron, ferritin and transferrin saturation, while hematological status and erythrocyte sedimentation rate measurement of systemic inflammation remained normal. Case 2 was unable to walk unaided until her EDSS improved from 6.5 to 4.0 over 12 months after implementation of the PSGT program, with amelioration of her suboptimal biochemical markers and changes to her diet and lifestyle, allowing her to regain independence. Genotype-phenotype correlation using a pathway panel of functional single nucleotide variants (SNVs) to facilitate clinical interpretation of whole exome sequencing (WES), elucidated the underlying metabolic pathways related to the biochemical deficits. A cure for MS will remain an elusive goal if separated from nutritional support required for production and maintenance of myelin, which can only be achieved by a lifelong investment in wellness.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33710528/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312195920&v=2.14.3\">33710528</a> | DOI:<a href=\"https://doi.org/10.1007/s11011-021-00712-9\">10.1007/s11011-021-00712-9</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33710528/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-08T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Metabolic Brain Disease", "authors": [ { "author_id": 174461, "given_name": "Susan J.", "family_name": "van Rensburg", "ORCID": "http://orcid.org/0000-0002-2437-8978", "country": null }, { "author_id": 252267, "given_name": "Coenraad", "family_name": "Hattingh", "ORCID": null, "country": null }, { "author_id": 174464, "given_name": "Kelebogile E.", "family_name": "Moremi", "ORCID": "http://orcid.org/0000-0003-1105-1578", "country": null }, { "author_id": 223783, "given_name": "Armand V.", "family_name": "Peeters", "ORCID": "http://orcid.org/0000-0002-7155-8226", "country": null }, { "author_id": 223784, "given_name": "Carel J.", "family_name": "van Heerden", "ORCID": "http://orcid.org/0000-0003-1786-7527", "country": "ZA" }, { "author_id": 174463, "given_name": "Rajiv T.", "family_name": "Erasmus", "ORCID": "http://orcid.org/0000-0001-6831-4215", "country": null }, { "author_id": 223785, "given_name": "Annalise E.", "family_name": "Zemlin", "ORCID": "http://orcid.org/0000-0001-7621-4679", "country": null }, { "author_id": 174465, "given_name": "Merlisa C.", "family_name": "Kemp", "ORCID": "http://orcid.org/0000-0001-5126-6982", "country": null }, { "author_id": 252270, "given_name": "Aye Aye", "family_name": "Khine", "ORCID": null, "country": null }, { "author_id": 252271, "given_name": "Felix C.V.", "family_name": "Potocnik", "ORCID": null, "country": null }, { "author_id": 252272, "given_name": "Lindiwe", "family_name": "Whati", "ORCID": null, "country": null }, { "author_id": 174466, "given_name": "Penelope", "family_name": "Engel-Hills", "ORCID": "http://orcid.org/0000-0002-1084-769X", "country": null }, { "author_id": 174462, "given_name": "Ronald", "family_name": "van Toorn", "ORCID": "http://orcid.org/0000-0002-2689-065X", "country": null }, { "author_id": 174467, "given_name": "Maritha J.", "family_name": "Kotze", "ORCID": "http://orcid.org/0000-0002-6050-2876", "country": null }, { "author_id": 329353, "given_name": "Clint", "family_name": "Johannes", "ORCID": "http://orcid.org/0009-0002-4358-9495", "country": "ZA" }, { "author_id": 329354, "given_name": "Mariaan", "family_name": "Jaftha", "ORCID": "http://orcid.org/0000-0003-2929-0972", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-13T00:59:21Z", "noun_phrases": [ "Pathology-supported genetic testing", "a method", "disability prevention", "multiple sclerosis", "MS", "Part II", "Insights", "two MS cases" ], "doi": "10.1007/s11011-021-00712-9", "access": "restricted", "takeaways": " Measurement of iron, vitamin B12, vitamin D, cholesterol and homocysteine levels identified biochemical deficits in both cases . Case 1 had an expanded disability status scale (EDSS) of 2.0 (no neurological sequelae) Case 2 was unable to walk unaided until her EDSS improved from 6.5 to 4.0 over 12 months after implementation of the PSGT program .", "categories": [] }, { "article_id": 518, "title": "Identification of lncRNAs associated with the pathogenesis of ankylosing spondylitis", "summary": "Background: Ankylosing spondylitis (AS) is a chronic autoimmune disease affecting the sacroiliac joint. To date, few studies have examined the association between long non-coding RNAs (lncRNAs) and AS pathogenesis. As such, we herein sought to characterize patterns of AS-related lncRNA expression and to evaluate the potential role played by these lncRNAs in this complex autoimmune context.MethodsWe conducted a RNA-seq analysis of peripheral blood mononuclear cell (PBMC) samples isolated from five AS patients and corresponding controls. These data were then leveraged to characterize AS-related lncRNA expression patterns. We further conducted GO and KEGG enrichment analyses of the parental genes encoding these lncRNAs, and we confirmed the validity of our RNA-seq data by assessing the expression of six lncRNAs via qRT-PCR in 15 AS and control patient samples. Pearson correlation analyses were additionally employed to examine the associations between the expression levels of these six lncRNAs and patient clinical index values.ResultsWe detected 56,575 total lncRNAs in AS and control patient samples during our initial RNA-seq analysis, of which 200 and 70 were found to be up- and down-regulated (FC > 2 or < 0.05; P < 0.05), respectively, in AS samples relative to controls. In qRT-PCR validation assays, we confirmed the significant upregulation of NONHSAT118801.2, ENST00000444046, and NONHSAT183847.1 and the significant downregulation of NONHSAT205110.1, NONHSAT105444.2, and NONHSAT051856.2 in AS patient samples. We further found the expression of NONHSAT118801.2 and NONHSAT183847.1 to be positively correlated with disease severity.ConclusionOverall, our findings highlight several lncRNAs that are specifically expressed in PBMCs of AS patients, indicating that they may play key functions in the pathogenesis of this autoimmune disease. Specifically, we determined that NONHSAT118801.2 and NONHSAT183847.1 may influence the occurrence and development of AS.", "link": "https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04119-6", "published_date": "2021-03-12T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Musculoskeletal Disorders", "authors": [ { "author_id": 296099, "given_name": "Dan", "family_name": "Huang", "ORCID": null, "country": null }, { "author_id": 201020, "given_name": "Jian", "family_name": "Liu", "ORCID": "http://orcid.org/0000-0003-3101-7553", "country": null }, { "author_id": 296100, "given_name": "Lei", "family_name": "Wan", "ORCID": null, "country": null }, { "author_id": 296101, "given_name": "Yanyan", "family_name": "Fang", "ORCID": null, "country": null }, { "author_id": 296102, "given_name": "Yan", "family_name": "Long", "ORCID": null, "country": null }, { "author_id": 248014, "given_name": "Ying", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 296103, "given_name": "Bingxi", "family_name": "Bao", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T19:59:51Z", "noun_phrases": [ "Identification", "lncRNAs", "the pathogenesis", "ankylosing spondylitis" ], "doi": "10.1186/s12891-021-04119-6", "access": "open", "takeaways": " Ankylosing spondylitis (AS) is a chronic autoimmune disease affecting the sacroiliac joint . Few studies have examined the association between long non-coding RNAs (lncRNAs) and AS pathogenesis .", "categories": [] }, { "article_id": 519, "title": "Isolated thoracic intramedullary Erdheim-Chester disease presenting with paraplegia: a case report and literature review", "summary": "Background: Erdheim-Chester disease (ECD) is a rare, idiopathic, systemic non-Langerhans cell histiocytosis involving long bone and visceral organs. Central nervous system (CNS) involvement is uncommon and most cases develop as a part of systemic disease. We present a rare case of variant ECD as an isolated intramedullary tumor.Case presentationA 75-year-old female patient with a medical history of diabetes and hypertension presented with sudden-onset flaccid paraparesis for 1 day. Neurological examination revealed grade 2–3 weakness in both legs, decreased deep tendon reflex, loss of anal tone, and numbness below T4. Leg weakness deteriorated to G1 before surgery. Preoperative magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) showed an intramedullary mass lesion at T2-T4 with no systemic lesion, which was heterogeneous enhancement pattern with cord swelling and edema from C7 to T6. Gross total removal was achieved for the white-gray-colored and soft-natured intramedullary mass lesion with an ill-defined boundary. Histological finding revealed benign histiocytic proliferation with foamy histiocytes and uniform nuclei. We concluded it as an isolated intramedullary ECD. The patient showed self-standing and walkable at 18-month with no evidence of recurrence and new lesion on spine MRI and whole-body FDG-PET/CT until sudden occurrence of unknown originated thoracic cord infarction.ConclusionsWe experienced an extremely rare case of isolated intramedullary ECD, which was controlled by surgical resection with no adjuvant therapy. Histological examination is the most important for final diagnosis, and careful serial follow-up after surgical resection is required to identify the recurrence and progression to systemic disease.", "link": "https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04061-7", "published_date": "2021-03-12T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Musculoskeletal Disorders", "authors": [ { "author_id": 244086, "given_name": "Ikchan", "family_name": "Jeon", "ORCID": null, "country": null }, { "author_id": 244087, "given_name": "Joon Hyuk", "family_name": "Choi", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T19:59:51Z", "noun_phrases": [ "Isolated thoracic intramedullary Erdheim-Chester disease", "paraplegia", "a case report", "literature review" ], "doi": "10.1186/s12891-021-04061-7", "access": "open", "takeaways": " Erdheim-Chester disease (ECD) is a rare, idiopathic, systemic non-Langerhans cell histiocytosis involving long bone and visceral organs . 75-year-old female patient with a medical history of diabetes and hypertension presented with sudden-onset flaccid paraparesis for 1 day . Neurological examination revealed grade 2–3 weakness in both legs, decreased deep tendon reflex, loss of anal tone, and numbness below T4 . MRI and FDG-PET/CT showed intramedullary mass lesion at T2-", "categories": [] }, { "article_id": 512, "title": "Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis", "summary": "<div><p>Farm Hosp. 2020 Dec 30;45(2):73-76. doi: 10.7399/fh.11567.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: Dimethyl fumarate is a medication approved for the treatment of relapsing-remitting multiple sclerosis. The purpose of the study was to evaluate the safety and persistence of dimethyl fumarate in clinical practice and analyze the occurrence of lymphopenia is patients treated with dimethyl fumarate over a period of at least 6 months.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHOD: This is a retrospective longitudinal observational study carried out between August 2015 and March 2019. The study cohort was made up of patients who had been treated with dimethyl fumarate for at least 6 months. Lymphocyte counts were recorded at different points of time (pre-treatment, at 3, 6, 12 months, and at the end of the study period). The evolution of lymphopenia was evaluated by means of a logistic regression statistical model. An analysis was performed of the relationship between a decreased lymphocyte count over the first 6 months of treatment and the development, by the end of the study, of grade II-III lymphopenia necessitating discontinuation of dimethyl fumarate. Other safety indicators were also evaluated including adverse events and interruptions or discontinuations of treatment. Persistence was determined by measuring the time to discontinuation of treatment.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: The study included a total of 55 patients, of whom 80% were female. The most common adverse events were lymphopenia (27), rubefaction (16), digestive symptoms (11), fatigue (9), headache (3) and sleep disturbances (2). Eleven subjects interrupted/discontinued their treatment during the study period; reasons were as follows: pregnancy (2), personal decision (2), John Cunningham virus infection (1), allergy to the drug (2), and lymphopenia (4). Median duration of treatment was 23 months (4-43 months). A statistically significant association was found between a lower lymphocyte count over the first 6 months of treatment and the development of severe lymphopenia by the end of the study [OR = 1.34 (0.35-2.60); 95% CI (p = 0.001)].</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The adverse events observed in the present study are in line with those reported in previous analyses. Lymphopenia was the most common adverse event. The persistence of the medication was similar to that found in pivotal trials. The significant association found between a decreased lymphocyte count over the first 6 months of treatment and the development of severe lymphopenia by the end of the study suggests a connection between both variables, which could be instrumental in being able to predict and even prevent the occurrence of such lymphopenias.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33709887/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">33709887</a> | DOI:<a href=\"https://doi.org/10.7399/fh.11567\">10.7399/fh.11567</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33709887/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2020-12-30T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T18:19:22Z", "noun_phrases": [ "Safety", "persistence", "dimethyl fumarate", "a treatment", "relapsing-remitting multiple-sclerosis" ], "doi": "10.7399/fh.11567", "access": "restricted", "takeaways": " Dimethyl fumarate is a medication approved for the treatment of relapsing-remitting multiple sclerosis . The most common adverse events were lymphopenia (27), rubefaction (16), digestive symptoms (11), fatigue (9), headache (3) and headache)", "categories": [ { "category_id": 5, "category_description": "Tecfidera is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used in adults and children from 13 years of age with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).\r\n\r\nTecfidera contains the active substance dimethyl fumarate.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera", "category_name": "Tecfidera", "category_slug": "tecfidera", "category_terms": [ "tecfidera", "dimethyl fumarate" ], "article_count": 163 } ] }, { "article_id": 516, "title": "U-Fiber Leukoencephalopathy Due to a Novel Mutation in the TACO1 Gene", "summary": "<div><p>Neurol Genet. 2021 Mar 9;7(2):e573. doi: 10.1212/NXG.0000000000000573. eCollection 2021 Apr.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33709035/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">33709035</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7943219/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">PMC7943219</a> | DOI:<a href=\"https://doi.org/10.1212/NXG.0000000000000573\">10.1212/NXG.0000000000000573</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33709035/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-09T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Neurology Genetics", "authors": [ { "author_id": 221260, "given_name": "Giacomo", "family_name": "Sferruzza", "ORCID": "http://orcid.org/0000-0003-2360-4803", "country": null }, { "author_id": 300639, "given_name": "Andrea", "family_name": "Del Bondio", "ORCID": null, "country": null }, { "author_id": 300640, "given_name": "Andrea", "family_name": "Citterio", "ORCID": null, "country": null }, { "author_id": 179340, "given_name": "Paolo", "family_name": "Vezzulli", "ORCID": "http://orcid.org/0000-0002-3568-4946", "country": null }, { "author_id": 244534, "given_name": "Simone", "family_name": "Guerrieri", "ORCID": null, "country": null }, { "author_id": 244469, "given_name": "Marta", "family_name": "Radaelli", "ORCID": null, "country": null }, { "author_id": 154939, "given_name": "Filippo", "family_name": "Martinelli Boneschi", "ORCID": "http://orcid.org/0000-0002-9955-1368", "country": null }, { "author_id": 143061, "given_name": "Massimo", "family_name": "Filippi", "ORCID": "http://orcid.org/0000-0002-5485-0479", "country": null }, { "author_id": 300641, "given_name": "Francesca", "family_name": "Maltecca", "ORCID": null, "country": null }, { "author_id": 300642, "given_name": "Maria Teresa", "family_name": "Bassi", "ORCID": null, "country": null }, { "author_id": 300643, "given_name": "Marina", "family_name": "Scarlato", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T18:19:22Z", "noun_phrases": [ "U-Fiber Leukoencephalopathy", "a Novel Mutation", "the TACO1 Gene" ], "doi": "10.1212/NXG.0000000000000573", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 515, "title": "Clinical characteristics, inflammation and coagulation status in patients with immunological disease-related chronic cerebrospinal venous insufficiency", "summary": "<div><p>Ann Transl Med. 2021 Feb;9(3):236. doi: 10.21037/atm-20-4201.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Immunological disease-related chronic cerebrospinal venous insufficiency (CCSVI) is rarely reported. This study aimed to analyze clinical characteristics, inflammation, and coagulation status in patients with immunological disease-related CCSVI.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Patients with CCSVI were enrolled from 2017 to 2019 and divided into three cohorts based on their immunological disease backgrounds, including groups with confirmed autoimmune disease, with suspected/subclinical autoimmune disease, and with non-immunological etiology. Immunological, inflammatory, and thrombophilia biomarker assay in blood samples were obtained. Mann-Whitney U test or Fisher's exact test was used to compare continuous variables or categorical variables between the CCSVI patients with or without the immunological etiology. Spearman's correlation analysis was conducted among age, baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), interleukin-6 (IL-6), C-reactive protein (CRP), and neuron-specific enolase (NSE) in the three groups.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: A total of 255 consecutive patients with CCSVI were enrolled, including three subgroups: CCSVI with confirmed autoimmune disease (n=41), CCSVI with suspected/subclinical autoimmune disease (n=116) and CCSVI with non-immunological etiology (n=98). In the first subgroup, a series of 41 cases was confirmed with eight different autoimmune diseases including antiphospholipid syndrome (n=18), Sjögren's syndrome (n=8), immunoglobulin G4-related disease (n=7), Behçet's disease (n=2), autoimmune hepatitis (n=2), Wegener's granulomatosis (n=2), systemic sclerosis (n=1) and AQP4 antibody-positive neuromyelitis optica spectrum disorder (n=1). Groups with immunological etiology did not show a higher incidence of thrombophilia or increased pro-inflammatory biomarkers (e.g., neutrophil, IL-6). However, patients with non-immunological etiology had a higher baseline level of CRP. Additionally, baseline PLR was moderately correlated to NLR and CRP in CCSVI patients with non-immunological etiology and suspected/subclinical autoimmune disease.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The formation of CCSVI may be based on the inflammatory process, facilitated by multiple risk factors, among which medical history of immunological diseases may play a significant role due to the intricate relationship between inflammation and coagulation. Moreover, CCSVI may also cause an independent inflammatory injury in venous walls, leading to focal stenosis or thrombus, without attacks from autoimmune antibodies.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33708863/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">33708863</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7940939/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">PMC7940939</a> | DOI:<a href=\"https://doi.org/10.21037/atm-20-4201\">10.21037/atm-20-4201</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33708863/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-02T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "AME Publishing Company", "container_title": "Annals of Translational Medicine", "authors": [ { "author_id": 295064, "given_name": "Si-Ying", "family_name": "Song", "ORCID": null, "country": null }, { "author_id": 295065, "given_name": "Duo", "family_name": "Lan", "ORCID": null, "country": null }, { "author_id": 295066, "given_name": "Xiao-Qin", "family_name": "Wu", "ORCID": null, "country": null }, { "author_id": 295067, "given_name": "Yu-Chuan", "family_name": "Ding", "ORCID": null, "country": null }, { "author_id": 295068, "given_name": "Xun-Ming", "family_name": "Ji", "ORCID": null, "country": null }, { "author_id": 295069, "given_name": "Ran", "family_name": "Meng", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T18:19:22Z", "noun_phrases": [ "Clinical characteristics", "inflammation", "coagulation", "status", "patients", "immunological disease-related chronic cerebrospinal venous insufficiency" ], "doi": "10.21037/atm-20-4201", "access": "open", "takeaways": " Chronic cerebrospinal venous insufficiency (CCSVI) is rarely reported . Study aimed to analyze clinical characteristics, inflammation, and coagulation status in patients with immunological disease-related CCSVI .", "categories": [] }, { "article_id": 506, "title": "Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis", "summary": "<div><p>Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Data on fertility after autologous hematopoietic stem cell transplantation (aHSCT) in women with multiple sclerosis (MS) are inconclusive. This study aims to report on post-aHSCT menstrual resumption in a multi-center MS-women cohort. Out of 43 women, 30 (70%) recovered menses after a mean time of 6.8 months. Older age (odds ratio (OR) = 0.5, <i>p</i> < 0.0001) and previous pulsed cyclophosphamide (OR = 0.44, <i>p</i> = 0.005) were independently associated with a reduced menstrual recovery probability. Conditioning regimens' intensity resulted not associated with post-procedure amenorrhea. Our results highlight younger age as significantly associated with menses recovery; proper fertility counseling for MS women candidated to aHSCT both prior- and post-transplantation is therefore warranted.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33709839/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">33709839</a> | DOI:<a href=\"https://doi.org/10.1177/13524585211000616\">10.1177/13524585211000616</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33709839/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-11T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 233488, "given_name": "Claudia", "family_name": "Massarotti", "ORCID": "http://orcid.org/0000-0003-1905-2786", "country": "IT" }, { "author_id": 233489, "given_name": "Elvira", "family_name": "Sbragia", "ORCID": "http://orcid.org/0000-0002-5903-8535", "country": null }, { "author_id": 148196, "given_name": "Giacomo", "family_name": "Boffa", "ORCID": "http://orcid.org/0000-0003-2220-9422", "country": null }, { "author_id": 233490, "given_name": "Caterina", "family_name": "Vercelli", "ORCID": "http://orcid.org/0000-0003-1633-186X", "country": "IT" }, { "author_id": 294107, "given_name": "Giovanni Bosco", "family_name": "Zimatore", "ORCID": null, "country": null }, { "author_id": 242434, "given_name": "Salvatore", "family_name": "Cottone", "ORCID": null, "country": null }, { "author_id": 148572, "given_name": "Jessica", "family_name": "Frau", "ORCID": "http://orcid.org/0000-0001-9068-9144", "country": null }, { "author_id": 311827, "given_name": "Annamaria", "family_name": "Raiola", "ORCID": null, "country": null }, { "author_id": 311828, "given_name": "Riccardo", "family_name": "Varaldo", "ORCID": null, "country": null }, { "author_id": 244021, "given_name": "Gianluigi", "family_name": "Mancardi", "ORCID": null, "country": null }, { "author_id": 155664, "given_name": "Matilde", "family_name": "Inglese", "ORCID": "http://orcid.org/0000-0002-9610-0297", "country": "IT" }, { "author_id": 311829, "given_name": "Paola", "family_name": "Anserini", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T18:19:22Z", "noun_phrases": [ "Menstrual cycle resumption", "female fertility", "autologous hematopoietic stem cell transplantation", "multiple sclerosis" ], "doi": "10.1177/13524585211000616", "access": "restricted", "takeaways": " Out of 43 women, 30 recovered menses after a mean time of 6.8 months . Older age and previous pulsed cyclophosphamide were independently associated with a reduced menstrual recovery probability . Conditioning regimens' intensity resulted not associated with post-procedure amenorrhea .", "categories": [ { "category_id": 12, "category_description": "Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and other stem cell therapies", "category_name": "Stem Cells", "category_slug": "stem-cells", "category_terms": [ "stem cells", "Autologous hematopoietic stem cell", "ahsct" ], "article_count": 233 }, { "category_id": 40, "category_description": "Autologous hematopoietic stem cell transplantation\n\nSearch terms: ahsct,Autologous hematopoietic stem cell transplantation,Bone marrow,Mesenchymal stem cells,Immunoablation", "category_name": "aHSCT", "category_slug": "ahsct", "category_terms": [ "ahsct", "Autologous hematopoietic stem cell transplantation", "Bone marrow", "Immunoablation" ], "article_count": 91 } ] }, { "article_id": 509, "title": "Spastic paresis of the arms and flaccid paralysis of the legs in secondary progressive multiple sclerosis", "summary": "<div><p>Nervenarzt. 2021 Mar 12. doi: 10.1007/s00115-021-01103-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33709169/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">33709169</a> | DOI:<a href=\"https://doi.org/10.1007/s00115-021-01103-2\">10.1007/s00115-021-01103-2</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33709169/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-10T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Der Nervenarzt", "authors": [ { "author_id": 300633, "given_name": "C.", "family_name": "Jacksch", "ORCID": null, "country": null }, { "author_id": 300634, "given_name": "S.", "family_name": "Paschen", "ORCID": null, "country": null }, { "author_id": 300635, "given_name": "S.", "family_name": "Peters", "ORCID": null, "country": null }, { "author_id": 300636, "given_name": "V.", "family_name": "Lindner", "ORCID": null, "country": null }, { "author_id": 300637, "given_name": "D.", "family_name": "Berg", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T18:19:22Z", "noun_phrases": [ "Spastic paresis", "the arms", "flaccid paralysis", "the legs", "secondary progressive multiple sclerosis" ], "doi": "10.1007/s00115-021-01103-2", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 505, "title": "Real-life clinical practice studies in multiple sclerosis", "summary": "<div><p>Farm Hosp. 2021 Mar 8;45(2):51-52. doi: 10.7399/fh.11663.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33709885/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">33709885</a> | DOI:<a href=\"https://doi.org/10.7399/fh.11663\">10.7399/fh.11663</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33709885/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-08T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T18:19:22Z", "noun_phrases": [ "Real-life clinical practice studies", "multiple sclerosis" ], "doi": "10.7399/fh.11663", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 503, "title": "Vaccinations in multiple sclerosis patients receiving disease-modifying drugs", "summary": "<div><p>Curr Opin Neurol. 2021 Mar 11. doi: 10.1097/WCO.0000000000000929. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PURPOSE OF REVIEW: This review focuses on new evidence supporting the global immunization strategy for multiple sclerosis (MS) patients receiving disease-modifying drugs (DMDs), including the recently available vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RECENT FINDINGS: New data strengthen the evidence against a causal link between MS and vaccination. Recent consensus statements agree on the need to start vaccination early. Timings for vaccine administration should be adjusted to ensure safety and optimize vaccine responses, given the potential interference of DMDs. Patients treated with Ocrelizumab (and potentially other B-cell depleting therapies) are at risk of diminished immunogenicity to vaccines. This has relevant implications for the upcoming vaccination against SARS-CoV-2.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">SUMMARY: An early assessment and immunization of MS patients allows optimizing vaccine responses and avoiding potential interference with treatment plans. Vaccinations are safe and effective but some specific considerations should be followed when vaccinating before, during, and after receiving immunotherapy. A time-window for vaccination taking into account the kinetics of B cell repopulation could potentially improve vaccine responses. Further understanding of SARS-CoV-2 vaccine response dynamics in MS patients under specific therapies will be key for defining the best vaccination strategy.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33709979/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210312131920&v=2.14.3\">33709979</a> | DOI:<a href=\"https://doi.org/10.1097/WCO.0000000000000929\">10.1097/WCO.0000000000000929</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33709979/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-05-31T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Ovid Technologies (Wolters Kluwer Health)", "container_title": "Current Opinion in Neurology", "authors": [ { "author_id": 243976, "given_name": "Susana", "family_name": "Otero-Romero", "ORCID": null, "country": null }, { "author_id": 186478, "given_name": "Alberto", "family_name": "Ascherio", "ORCID": "http://orcid.org/0000-0002-0585-3294", "country": null }, { "author_id": 167428, "given_name": "Christine", "family_name": "Lebrun-Frénay", "ORCID": "http://orcid.org/0000-0002-3713-2416", "country": "FR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T18:19:22Z", "noun_phrases": [ "Vaccinations", "multiple sclerosis patients", "disease-modifying drugs" ], "doi": "10.1097/WCO.0000000000000929", "access": "restricted", "takeaways": " New data strengthen the evidence against a causal link between MS and vaccination . Timings for vaccine administration should be adjusted to ensure safety and optimize vaccine responses .", "categories": [] } ] }